Ken Griffin Provention Bio, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2023

May 15, 2023
SELL
$6.7 - $24.21 $215,740 - $779,562
-32,200 Reduced 53.14%
28,400 $684,000
Q4 2022

Feb 14, 2023
BUY
$4.52 - $10.57 $88,591 - $207,172
19,600 Added 47.8%
60,600 $640,000
Q3 2022

Nov 14, 2022
BUY
$3.43 - $5.62 $14,063 - $23,042
4,100 Added 11.11%
41,000 $185,000

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0
View Full List

About Provention Bio, Inc.

PRVB Quotes by TradingView
  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email